Company: BDRX
Filing Date: 2025-09-12
Form Type: 424B3
Source: 0001214659-25-013675
Chunk: 3

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-09-12
Form: 424B3
Chunk 3
---
 website atwww.biodexapharma.com.

OPERATIONAL HIGHLIGHTS

The Company announced
the following in the six months ended June 30, 2025:

| · | Allowance by the US Patent and Trademark Office                                                                              
 of patent application No. 17/391-495 “Oral Rapamycin Nanoparticle Preparations and Use”, exclusively licensed to the Company 
 by Emtora Biosciences .                                                                                                      |

| · | Appointment of Precision for Medicine, LLC as                                                                                      
 the clinical research organization to conduct the European component of the upcoming registrational Phase 3 study of eRapa in FAP. |

| · | A successful Type C meeting with the US Food                                                                   
 and Drug Administration regarding the protocol for the Company’s registrational Phase 3 study of eRapa in FAP. |

| · | Orphan Drug Designation granted for eRapa in 
 FAP by the European Commission.              |

| · | Recruitment of the first patient in a Phase 2a                                                                                       
 study of tolimidone in Type 1 Diabetes in an Investigator Initiated Trial conducted by the University of Alberta Diabetes Institute. |

| · | Selection of ‘Serenta’ as                                                                                                                   
 the brand name for its Phase 3 clinical study of eRapa in FAP together with launch of a dedicated website, www.serentatrial.com, to provide 
 information and resources for patients, caregivers, and healthcare professionals.                                                           |

| · | Activation of the first clinical study site in     
 the US for its Serenta trial in patients with FAP. |

Post period end:

| · | Filing of a Clinical Trial Application with the                       
 European Medicines Agency for its Serenta trial in patients with FAP. |

| · | Enrolment of first patients in the Serenta trial by the           
 Pan American Center for Oncology Trials in San Juan, Puerto Rico. |

| 2 |

FINANCIAL HIGHLIGHTS

| · | Signing of a $35 million Equity Line of Credit with                                                                                           
 C/M Capital Master Fund LP, or C/M, pursuant to which the Company has the right, but not the obligation, to sell to C/M, and C/M is obligated 
 to purchase newly issued ADSs for a period of 36 months.                                                                                      |

| · | The Company’s collaboration partner, Emtora                                                                                         
 Biosciences, was awarded an additional grant of $3.0 million from the Cancer Prevention & Research Institute of Texas